Inferior vena cava filter thromboprophylaxis in surgical cancer patients
- PMID: 38865285
- DOI: 10.1002/jso.27734
Inferior vena cava filter thromboprophylaxis in surgical cancer patients
Abstract
Background and objectives: This study evaluated the utilization and outcomes of inferior vena cava (IVC) filters as thromboprophylaxis in cancer patients undergoing surgery.
Methods: This single-center retrospective study analyzed baseline patient characteristics and clinical outcomes of surgical cancer patients who received perioperative prophylactic IVC filters. Primary clinical endpoints included venous thromboembolism (VTE) incidence and filter complications. A statistical correlative analysis was conducted to identify risk factors related to pulmonary embolism (PE), deep vein thrombosis (DVT), and filter thrombi, as well as advanced technique filter removal and mortality at 6 months.
Results: A total of 252 surgical oncology patients (median age, 59; female 51%) received IVC filters for the perioperative prevention of PE. Primary surgical sites included spine (n = 91, 36%), orthopedic extremity/joint (n = 49, 19%), genitourinary (n = 47, 19%), brain/cranial (n = 40, 16%), abdominal (n = 18, 7%), multisite (n = 4, 2%), and chest (n = 3, 1%). Moreover, 15% of patients experienced DVTs in the postplacement preretrieval period, while 2% (n = 6) of patients experienced definitive PEs. A total of 36% of IVC filters were ultimately retrieved, with an average filter dwell time of 7.4 months. Complications occurred in one retrieval.
Conclusion: Prophylactic perioperative IVC filters in surgical cancer patients resulted in minimal complications while ultimately resulting in a low incidence of PE.
Keywords: IVC filters; PE; VTE; cancer; perioperative; surgery.
© 2024 The Author(s). Journal of Surgical Oncology published by Wiley Periodicals LLC.
References
REFERENCES
-
- Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism. Am J Prev Med. 2010;38(4 suppl):S495‐S501. doi:10.1016/j.amepre.2009.12.017
-
- Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet. 2021;398(10294):64‐77. doi:10.1016/S0140-6736(20)32658-1
-
- Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer‐associated venous thrombosis. Blood. 2013;122(10):1712‐1723. doi:10.1182/blood-2013-04-460121
-
- Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490‐493. doi:10.1016/j.thromres.2009.12.023
-
- Marshall A, Levine M, Hill C, et al. Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D trial (SELECT‐D: 12m). J Thromb Haemost. 2020;18(4):905‐915. doi:10.1111/jth.14752
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
